A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

Conditions:   Leukemia;   Lymphoma;   Lymphoma, B-Cell Intervention:   Biological: CAR T-Cell Infusion Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Moussab Damlaj, Mohammad Snnallah, Razan Bashir, Inaam Shehab Eddine, Bader Alahmari, Hind Salama, Ahmed Alaskar, Ayman Alhejazi, Mohsen Alzahrani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Mahmut Yeral, Pelin Aytan, Burcu Gungor, Can Boga, Ali Unal, Yener Koc, Leylagul Kaynar, Nurhilal Buyukkurt, Bulent Eser, Hakan Ozdoğu
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2020Source: The Lancet Haematology, Volume 7, Issue 10Author(s): Koju Kamoi, Seiko Kato, Kaoru Uchimaru, Arinobu Tojo, Kyoko Ohno-Matsui
Source: The Lancet Haematology - Category: Hematology Source Type: research
Conditions:   Leukemia;   Lymphoma;   Lymphoma, B-Cell Intervention:   Biological: CAR T-Cell Infusion Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Chimeric antigen receptor CD-19 T cell (CAR-T) therapy is approved in the United States for the treatment of acute lymphocytic leukemia (ALL) [1] and aggressive B cell lymphomas [2-4]. Although clinically effective, these agents are associated with substantial morbidity and mortality due to adverse events [5-7]. The most common side effect is cytokine release syndrome (CRS) [8], which is a phenomenon noted within the first 2 weeks of therapy of CAR-T infusion, resulting in a systemic inflammatory response syndrome with fevers, hypotension, and/or hypoxia [9].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Conditions:   Leukemia;   Lymphoma;   Lymphoma, B-Cell Intervention:   Biological: CAR T-Cell Infusion Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 19 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Panayotis Kaloyannidis, Rawan Omari, Eman Eldebawy, Eshrak Al Shaibani, John Apostolidis, Taghreed Hindi, Heba Raslan, Ayed Al Garni, Ahmed Al Buali, Khalid Al Anezi, Hani Al Hashmi
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 19 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Lalit Kumar, Naresh Gundu, Harish Kancharia, Ranjit Kumar Sahoo, Prabhat Singh Malik, Atul Sharma, Ritu Gupta, Omdutt Sharma, Ahitagni Biswas, Rakesh Kumar, Sanjay Thulkar, Saumyaranjan Mallick, AIIMS Myeloma Group
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 September 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Al-Ola Abdallah, Ghulam Rehman Mohyuddin, Zahra Mahmoudjafari, Shebli Atrash, Hameem Kawsar, Monia Sigle, Leyla Shune, Joseph McGuirk, Siddhartha Ganguly
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Leukemia | Lymphoma | Research | Transplants